Thomas Hallam, Ph.D.

Chief Executive Officer

Dr. Hallam brings broad pharmaceutical industry expertise to his role with Leading BioSciences, having leadership experience in virtually every stage of pre-clinical research, clinical development and regulatory affairs. Prior to joining Leading BioSciences, he served as director of therapeutic programs and head of new product development for Mesoblast Inc., directing commercialization strategy and product development for the company’s adult stem cell products. He previously served in the San Francisco office of C1 Consulting, assisting pharmaceutical companies launch and commercialize new products, and as medical director at Saatchi & Saatchi Healthcare in New York.  Under his leadership at Saatchi & Saatchi, the healthcare marketing team was named “Best Large Marketing Team of 2010” by Medical Marketing and Media Magazine. Past experience also includes leading the pharmacology group at Helicon Therapeutics, where he directed research operations at four U.S. locations and managed global CRO operations. Over the course of his career, he has successfully advanced eight drugs from pre-clinical research to Phase 2 trials, designing clinical studies to maximize data for regulatory approval, business development and marketing. He has served as a consultant and advisor to some of the world’s leading healthcare companies, including Roche/Genentech, Pfizer, Sanofi, Astra-Zeneca, Bausch & Lomb, Somaxon, CogMed, Pearson, Dart Neuroscience, and Ogilvy CommonHealth.

Dr. Hallam is a former Howard Hughes Medical Institute Research fellow. He received his Ph.D. in neuroscience from University California, Davis, earned a master’s degree in business administration from the University of Southern California, and holds a bachelor’s degree in biology from the University of Illinois at Urbana-Champaign.